69:@0.890196:0.957873:0.907378:0.957873:0.907378:0.938882:0.890196:0.938882:0.008591:0.008591
3:@0.941813:0.310836:0.963291:0.310836:0.963291:0.263358:0.941813:0.263358:0.021478
PATIENT-DERIVED OVARIAN CANCER ORGANOIDS MIMIC CLINICAL RESPONSE AND:@0.411230:0.057372:0.882353:0.057372:0.882353:0.040253:0.411230:0.040253:0.007583:0.007097:0.006387:0.003511:0.006985:0.008759:0.005640:0.005155:0.008423:0.006985:0.008423:0.003511:0.007620:0.006985:0.008423:0.002988:0.008328:0.006966:0.007919:0.008423:0.003511:0.007919:0.008759:0.002988:0.008178:0.007919:0.008759:0.008255:0.006985:0.008423:0.002988:0.008442:0.008311:0.008292:0.007919:0.008759:0.008442:0.003511:0.008423:0.007807:0.002988:0.011112:0.003511:0.011112:0.003511:0.008255:0.002988:0.008255:0.006481:0.003511:0.008759:0.003511:0.008177:0.007919:0.006294:0.002988:0.008423:0.006871:0.007807:0.008050:0.008442:0.008759:0.007807:0.006985:0.002801:0.007919:0.008759:0.008423
EXHIBIT HETEROGENEOUS INTER- AND INTRAPATIENT DRUG RESPONSES:@0.468171:0.073247:0.882352:0.073247:0.882352:0.056128:0.468171:0.056128:0.006985:0.007527:0.008685:0.003511:0.008236:0.003511:0.006201:0.002988:0.008685:0.006985:0.006387:0.006985:0.008309:0.008442:0.008404:0.006985:0.008759:0.006985:0.008442:0.008367:0.007807:0.002988:0.003511:0.008759:0.006387:0.006985:0.008423:0.005155:0.002800:0.007919:0.008759:0.008423:0.002988:0.003511:0.008759:0.006387:0.008423:0.007919:0.007581:0.007097:0.006387:0.003511:0.006985:0.008759:0.006201:0.002988:0.008423:0.008367:0.008367:0.008404:0.002988:0.008423:0.006873:0.007807:0.008050:0.008442:0.008759:0.007807:0.006871:0.007807
PDOs derived from individual patients revealed intrapatient drug response :@0.147059:0.122511:0.820248:0.122511:0.820248:0.099351:0.147059:0.099351:0.010733:0.011231:0.011256:0.010409:0.003984:0.011231:0.009363:0.011231:0.004856:0.010160:0.009363:0.011231:0.003984:0.008840:0.011079:0.011256:0.014817:0.003984:0.004856:0.011679:0.011231:0.004856:0.010160:0.004856:0.011231:0.011004:0.010558:0.008442:0.003984:0.010110:0.009463:0.008616:0.004856:0.009363:0.011679:0.008516:0.010409:0.003984:0.011231:0.009363:0.010160:0.009363:0.010558:0.008691:0.009363:0.011231:0.003984:0.004856:0.011679:0.008616:0.011231:0.010558:0.010105:0.009463:0.008616:0.004856:0.009363:0.011679:0.008367:0.003984:0.011231:0.011156:0.011156:0.011206:0.003984:0.011231:0.009214:0.010409:0.010733:0.011256:0.011679:0.010409:0.009363:0.003984
heterogeneity:@0.147059:0.141914:0.273710:0.141914:0.273710:0.118754:0.147059:0.118754:0.011579:0.009363:0.008616:0.009363:0.011081:0.011256:0.011206:0.009363:0.011679:0.009363:0.004856:0.008616:0.010309
In addition to assessing interpatient drug response heterogeneity, we examined intra-:@0.147059:0.191481:0.882353:0.191481:0.882353:0.171108:0.147059:0.171108:0.006894:0.011756:0.006391:0.009291:0.011322:0.011391:0.005273:0.006437:0.005547:0.010843:0.011756:0.006391:0.006209:0.011048:0.006391:0.009291:0.007533:0.007875:0.009039:0.007533:0.007601:0.005615:0.011459:0.009861:0.006391:0.005615:0.011391:0.006209:0.009039:0.007967:0.011365:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.006391:0.011391:0.007967:0.011413:0.009861:0.006391:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.006391:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.007989:0.004497:0.006391:0.014518:0.009039:0.006391:0.009108:0.010089:0.009085:0.017645:0.005615:0.011596:0.009108:0.011391:0.006391:0.005615:0.011391:0.006437:0.007896:0.009293:0.007533
patient drug response heterogeneity. For seven individual patients, two to four PDOs :@0.147059:0.212059:0.886368:0.212059:0.886368:0.191686:0.147059:0.191686:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.006414:0.011391:0.007964:0.011413:0.009861:0.006414:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.006414:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.007989:0.004497:0.006414:0.010683:0.010843:0.007807:0.006414:0.007875:0.009336:0.009633:0.009039:0.011756:0.006414:0.005615:0.011594:0.011391:0.005547:0.009838:0.005547:0.011048:0.011596:0.009405:0.005250:0.006414:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004497:0.006414:0.006437:0.014518:0.011048:0.006414:0.006209:0.011048:0.006414:0.006024:0.010822:0.011413:0.007807:0.006414:0.011664:0.016504:0.016253:0.007670:0.004109
were derived from distinct cancer lesions at a single time point. For one additional pa-:@0.147059:0.232638:0.882353:0.232638:0.882353:0.212265:0.147059:0.212265:0.014518:0.009039:0.007442:0.009039:0.005319:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.005319:0.006412:0.007442:0.010845:0.017645:0.005319:0.011391:0.005615:0.007508:0.006437:0.005615:0.011596:0.009108:0.006437:0.005319:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.005319:0.005182:0.009039:0.007601:0.005547:0.010843:0.011619:0.007670:0.005319:0.008811:0.006437:0.005319:0.009291:0.005319:0.007601:0.005615:0.011459:0.009930:0.005182:0.009039:0.005319:0.006437:0.005615:0.017485:0.009039:0.005319:0.011502:0.010845:0.005615:0.011388:0.006437:0.004497:0.005319:0.010683:0.010843:0.007807:0.005319:0.010843:0.011596:0.009039:0.005319:0.009291:0.011322:0.011391:0.005273:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.005319:0.011368:0.009384:0.007533
tient, three PDOs were derived at subsequent time points (:@0.147059:0.253217:0.636326:0.253217:0.636326:0.232844:0.147059:0.232844:0.006437:0.005547:0.009039:0.011391:0.006437:0.004497:0.004040:0.006620:0.011459:0.007442:0.009108:0.009039:0.004040:0.011662:0.016504:0.016253:0.007670:0.004040:0.014518:0.009039:0.007442:0.009039:0.004040:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.004040:0.008811:0.006437:0.004040:0.007510:0.011345:0.010934:0.007875:0.009108:0.010703:0.011347:0.009039:0.011391:0.006437:0.004040:0.006437:0.005615:0.017485:0.009039:0.004040:0.011505:0.010843:0.005615:0.011391:0.006437:0.007670:0.004040:0.006939
Table S1:@0.636343:0.253217:0.709822:0.253217:0.709822:0.232084:0.636343:0.232084:0.011413:0.009679:0.011528:0.005935:0.009473:0.003949:0.010592:0.010911
, heterogeneity com-:@0.709825:0.253217:0.882353:0.253217:0.882353:0.232844:0.709825:0.232844:0.004497:0.004040:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.004040:0.008994:0.010843:0.017648:0.007533
parison). To set a threshold for differential drug response, we first assessed the extent of :@0.147059:0.273795:0.886439:0.273795:0.886439:0.253422:0.147059:0.253422:0.011368:0.009085:0.007807:0.005615:0.007875:0.010843:0.011756:0.006939:0.004497:0.004611:0.010866:0.011048:0.004611:0.007875:0.009131:0.006437:0.004611:0.009291:0.004611:0.006620:0.011459:0.007442:0.009039:0.007556:0.011299:0.010936:0.005182:0.011391:0.004611:0.006026:0.010843:0.007807:0.004611:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009402:0.005250:0.004611:0.011391:0.007967:0.011413:0.009861:0.004611:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007873:0.008745:0.004497:0.004611:0.014518:0.009039:0.004611:0.005684:0.005684:0.007624:0.007510:0.006437:0.004611:0.009291:0.007533:0.007875:0.009039:0.007533:0.007875:0.009106:0.011391:0.004611:0.006620:0.011299:0.009039:0.004611:0.009108:0.010089:0.006209:0.009039:0.011391:0.006437:0.004611:0.010843:0.006209:0.004109
biological variability. We observed low drug response variability across biological repli-:@0.147059:0.294374:0.882353:0.294374:0.882353:0.274001:0.147059:0.274001:0.010820:0.005547:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009405:0.005250:0.004794:0.009838:0.009085:0.007807:0.005798:0.009108:0.010820:0.005752:0.005250:0.005271:0.006437:0.007989:0.004497:0.004794:0.018652:0.009039:0.004794:0.010957:0.010934:0.007873:0.009039:0.008400:0.009633:0.009108:0.011391:0.004794:0.005182:0.010866:0.014723:0.004794:0.011391:0.007964:0.011413:0.009861:0.004794:0.007444:0.009039:0.007510:0.011505:0.010840:0.011621:0.007873:0.009039:0.004794:0.009838:0.009085:0.007807:0.005798:0.009108:0.010820:0.005750:0.005250:0.005273:0.006437:0.009724:0.004794:0.009291:0.008994:0.007442:0.010957:0.007533:0.007670:0.004794:0.010820:0.005545:0.010936:0.005179:0.011048:0.009861:0.005547:0.009108:0.009405:0.005250:0.004794:0.007442:0.009131:0.011162:0.005250:0.005714:0.007533
cates (N=84) with an IC50-value correlation coefficient of R²=0.82 and mean IC50-fold :@0.147059:0.314953:0.886370:0.314953:0.886370:0.294580:0.147059:0.294580:0.009108:0.008811:0.006209:0.009039:0.007670:0.004497:0.006939:0.016230:0.011779:0.010432:0.010432:0.006939:0.004497:0.014723:0.005273:0.006620:0.011459:0.004497:0.009085:0.011756:0.004497:0.006825:0.014678:0.010432:0.010432:0.007533:0.009838:0.009405:0.004908:0.011345:0.009039:0.004497:0.008994:0.010843:0.007807:0.007442:0.008948:0.005430:0.008813:0.006437:0.005545:0.010843:0.011756:0.004497:0.008994:0.011276:0.009039:0.005692:0.005692:0.005623:0.008994:0.005547:0.009039:0.011391:0.006437:0.004497:0.010843:0.006209:0.004497:0.013376:0.007099:0.011779:0.010432:0.004497:0.010432:0.010432:0.004497:0.009085:0.011596:0.011391:0.004497:0.017485:0.009291:0.009085:0.011756:0.004497:0.006825:0.014678:0.010432:0.010432:0.007533:0.006026:0.010934:0.005182:0.011391:0.004109
change of 2.5±1.5 (range=1.0-7.3) (:@0.147059:0.335531:0.438146:0.335531:0.438146:0.315159:0.147059:0.315159:0.008765:0.011391:0.009085:0.011459:0.009656:0.009039:0.003538:0.010843:0.006209:0.003538:0.010432:0.004497:0.010432:0.011779:0.010432:0.004497:0.010432:0.003538:0.006939:0.007896:0.009085:0.011461:0.009656:0.009039:0.011779:0.010432:0.004497:0.010432:0.007533:0.010432:0.004497:0.010432:0.006939:0.003538:0.006939
Figure S3B-C; Table S4:@0.438179:0.335531:0.638987:0.335531:0.638987:0.314399:0.438179:0.314399:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.003470:0.010592:0.010911:0.013765:0.007213:0.014769:0.005433:0.003470:0.011413:0.009679:0.011528:0.005935:0.009473:0.003470:0.010592:0.010911
), therefore, a ten-fold change :@0.638982:0.335531:0.886424:0.335531:0.886424:0.315159:0.638982:0.315159:0.006939:0.004497:0.003538:0.006620:0.011299:0.009039:0.007442:0.009039:0.006026:0.010843:0.007442:0.008743:0.004497:0.003538:0.009291:0.003538:0.006209:0.009039:0.011756:0.007533:0.006026:0.010934:0.005182:0.011391:0.003538:0.008765:0.011391:0.009085:0.011459:0.009656:0.009039:0.004109
in IC50-value was chosen as a stringent cut-off for differential drug response.:@0.147059:0.356110:0.790904:0.356110:0.790904:0.335737:0.147059:0.335737:0.005615:0.011756:0.004109:0.006825:0.014678:0.010432:0.010432:0.007533:0.009838:0.009402:0.004908:0.011345:0.009039:0.004109:0.014723:0.009291:0.007670:0.004109:0.008765:0.011299:0.010957:0.007875:0.009039:0.011756:0.004109:0.009291:0.007670:0.004109:0.009291:0.004109:0.007508:0.006437:0.007807:0.005615:0.011459:0.009656:0.009039:0.011393:0.006437:0.004109:0.009106:0.011071:0.006437:0.007533:0.010843:0.005969:0.005969:0.004109:0.006026:0.010843:0.007807:0.004109:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009402:0.005250:0.004109:0.011391:0.007967:0.011413:0.009861:0.004109:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.008743:0.004497
While homogeneous responses were observed to a subset of drugs and drug combina-:@0.147059:0.397268:0.882353:0.397268:0.882353:0.376895:0.147059:0.376895:0.020704:0.011459:0.005752:0.005182:0.009039:0.005273:0.011299:0.010843:0.017485:0.011048:0.009656:0.009039:0.011596:0.009108:0.010820:0.011413:0.007670:0.005273:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007873:0.009039:0.007670:0.005273:0.014518:0.009039:0.007442:0.009039:0.005273:0.010957:0.010934:0.007875:0.009039:0.008398:0.009635:0.009106:0.011391:0.005273:0.006209:0.011048:0.005273:0.009291:0.005273:0.007510:0.011345:0.010934:0.007875:0.009131:0.006437:0.005273:0.010843:0.006209:0.005273:0.011391:0.007967:0.011413:0.009724:0.007670:0.005273:0.009085:0.011596:0.011391:0.005273:0.011391:0.007964:0.011413:0.009861:0.005273:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.009409:0.007533
tions; carboplatin combined with gemcitabine, adavosertib, or olaparib, carboplatin, :@0.147059:0.417846:0.886528:0.417846:0.886528:0.397473:0.147059:0.397473:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497:0.008035:0.009108:0.009085:0.007715:0.011254:0.010820:0.011162:0.005433:0.008811:0.006437:0.005615:0.011756:0.008035:0.008994:0.010843:0.017396:0.010818:0.005615:0.011598:0.009106:0.011391:0.008035:0.014723:0.005271:0.006620:0.011459:0.008035:0.009656:0.009039:0.017485:0.008994:0.005273:0.006551:0.009108:0.010820:0.005615:0.011596:0.008743:0.004497:0.008035:0.009291:0.011573:0.008925:0.009633:0.010957:0.007875:0.009039:0.007967:0.006437:0.005547:0.010249:0.004497:0.008035:0.010843:0.007807:0.008035:0.010936:0.005433:0.008811:0.011365:0.009085:0.007807:0.005547:0.010249:0.004497:0.008035:0.009108:0.009085:0.007715:0.011251:0.010820:0.011162:0.005433:0.008811:0.006437:0.005615:0.011756:0.004497:0.004109
olaparib, niraparib, rucaparib, alpelisib, AZD-8055, flavopiridol, pictilisib, and vemu-:@0.147059:0.438425:0.882353:0.438425:0.882353:0.418052:0.147059:0.418052:0.010934:0.005433:0.008811:0.011368:0.009085:0.007807:0.005547:0.010249:0.004497:0.006939:0.011756:0.005615:0.007898:0.008811:0.011365:0.009087:0.007807:0.005547:0.010247:0.004497:0.006939:0.007967:0.011345:0.009108:0.008811:0.011368:0.009085:0.007807:0.005547:0.010249:0.004497:0.006939:0.009405:0.004908:0.011505:0.008948:0.005250:0.005615:0.007601:0.005547:0.010249:0.004497:0.006939:0.014929:0.012966:0.016139:0.007533:0.010432:0.010432:0.010432:0.010432:0.004497:0.006939:0.005638:0.005821:0.008925:0.009633:0.010820:0.011071:0.005615:0.007807:0.005545:0.011324:0.010934:0.004976:0.004497:0.006939:0.011071:0.005547:0.009106:0.006437:0.005752:0.005250:0.005615:0.007601:0.005547:0.010249:0.004497:0.006939:0.009085:0.011596:0.011391:0.006939:0.009635:0.009039:0.017280:0.011482:0.007533
rafenib (:@0.147059:0.459004:0.218895:0.459004:0.218895:0.438631:0.147059:0.438631:0.007898:0.009085:0.006026:0.009039:0.011756:0.005547:0.011025:0.004520:0.006939
Figure S4:@0.218891:0.459004:0.302994:0.459004:0.302994:0.437871:0.218891:0.437871:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004415:0.010592:0.010911
), all related PDOs exhibited differential drug response to at least one :@0.302995:0.459004:0.886487:0.459004:0.886487:0.438631:0.302995:0.438631:0.006939:0.004497:0.004520:0.009405:0.005385:0.005250:0.004520:0.007442:0.008948:0.005433:0.008811:0.006209:0.009108:0.011391:0.004520:0.011664:0.016504:0.016253:0.007670:0.004520:0.009108:0.010089:0.011459:0.005545:0.010820:0.005273:0.006209:0.009108:0.011391:0.004520:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005796:0.009405:0.005250:0.004520:0.011391:0.007967:0.011413:0.009861:0.004520:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004520:0.006209:0.011048:0.004520:0.008811:0.006437:0.004520:0.005182:0.009291:0.009291:0.007510:0.006437:0.004520:0.010843:0.011596:0.009039:0.004109
drug, as defined by a >10-fold change in IC50-value (:@0.147059:0.479582:0.610746:0.479582:0.610746:0.459209:0.147059:0.459209:0.011391:0.007967:0.011413:0.009679:0.004497:0.006277:0.009291:0.007670:0.006266:0.011322:0.009039:0.005684:0.005684:0.011596:0.009108:0.011391:0.006277:0.010843:0.009724:0.006277:0.009291:0.006277:0.011550:0.010432:0.010432:0.007533:0.006024:0.010934:0.005182:0.011391:0.006277:0.008765:0.011391:0.009085:0.011459:0.009656:0.009039:0.006277:0.005615:0.011756:0.006277:0.006825:0.014678:0.010432:0.010432:0.007533:0.009838:0.009402:0.004908:0.011345:0.009039:0.006277:0.006939
Figure 4:@0.610674:0.479582:0.685899:0.479582:0.685899:0.458450:0.610674:0.458450:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.006129:0.010911
). In the seven patients :@0.685898:0.479582:0.886498:0.479582:0.886498:0.459209:0.685898:0.459209:0.006939:0.004497:0.006277:0.006894:0.011756:0.006277:0.006620:0.011299:0.009039:0.006277:0.007873:0.009336:0.009633:0.009039:0.011756:0.006277:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004109
of whom multiple PDOs were derived at the same time point, differential response to :@0.147059:0.500161:0.886373:0.500161:0.886373:0.479788:0.147059:0.479788:0.010843:0.006209:0.005958:0.014792:0.011299:0.010843:0.017645:0.005958:0.017280:0.011550:0.004908:0.006437:0.005273:0.011162:0.005182:0.009039:0.005958:0.011664:0.016504:0.016253:0.007670:0.005958:0.014518:0.009039:0.007442:0.009039:0.005958:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.005958:0.008813:0.006437:0.005958:0.006617:0.011302:0.009039:0.005958:0.007944:0.009085:0.017485:0.009039:0.005958:0.006437:0.005615:0.017485:0.009039:0.005958:0.011505:0.010843:0.005615:0.011391:0.006437:0.004497:0.005958:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009402:0.005250:0.005958:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.005958:0.006209:0.011048:0.004109
mono-treatment was observed 11/36 times (31%). Importantly, in six cases, one of the :@0.147059:0.520740:0.886553:0.520740:0.886553:0.500367:0.147059:0.500367:0.017485:0.010843:0.011596:0.011048:0.007533:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.005524:0.014723:0.009291:0.007670:0.005524:0.010957:0.010932:0.007875:0.009039:0.008400:0.009633:0.009108:0.011391:0.005524:0.010432:0.010432:0.007099:0.010432:0.010432:0.005524:0.006437:0.005615:0.017485:0.009039:0.007670:0.005524:0.006939:0.010432:0.010432:0.015043:0.006939:0.004497:0.005524:0.006894:0.017280:0.011505:0.010843:0.007967:0.006551:0.009085:0.011391:0.006620:0.005182:0.007989:0.004497:0.005524:0.005615:0.011756:0.005524:0.007601:0.005615:0.010089:0.005524:0.009108:0.009291:0.007875:0.009039:0.007670:0.004497:0.005524:0.010840:0.011598:0.009039:0.005524:0.010843:0.006209:0.005524:0.006620:0.011299:0.009039:0.004109
samples exhibited high responsiveness whereas a related sample exhibited low respon-:@0.147059:0.541319:0.882353:0.541319:0.882353:0.520946:0.147059:0.520946:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.005433:0.009108:0.010089:0.011459:0.005547:0.010820:0.005273:0.006209:0.009108:0.011391:0.005433:0.011459:0.005615:0.009927:0.011459:0.005433:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007601:0.005547:0.009633:0.009039:0.011598:0.009039:0.007533:0.007670:0.005433:0.014792:0.011299:0.009039:0.007442:0.009291:0.009291:0.007670:0.005433:0.009291:0.005433:0.007442:0.008948:0.005430:0.008813:0.006209:0.009106:0.011391:0.005433:0.007944:0.009085:0.017280:0.011162:0.005184:0.009039:0.005433:0.009106:0.010089:0.011459:0.005547:0.010820:0.005273:0.006209:0.009108:0.011391:0.005433:0.005182:0.010866:0.014723:0.005433:0.007442:0.009039:0.007510:0.011505:0.010843:0.011733:0.007533
siveness to the tested drugs.:@0.147059:0.561897:0.377493:0.561897:0.377493:0.541524:0.147059:0.541524:0.007601:0.005547:0.009633:0.009039:0.011596:0.009039:0.007533:0.007670:0.004109:0.006209:0.011048:0.004109:0.006620:0.011299:0.009039:0.004109:0.006209:0.009039:0.007510:0.006209:0.009108:0.011391:0.004109:0.011391:0.007967:0.011413:0.009722:0.007670:0.004497
To examine the impact of intratumor genetic heterogeneity on phenotypic heterogeneity, :@0.147059:0.603055:0.886421:0.603055:0.886421:0.582682:0.147059:0.582682:0.010866:0.011048:0.003287:0.009108:0.010089:0.009085:0.017645:0.005615:0.011596:0.009039:0.003287:0.006620:0.011302:0.009039:0.003287:0.005615:0.017278:0.011368:0.009291:0.009108:0.006437:0.003287:0.010843:0.006209:0.003287:0.005615:0.011391:0.006437:0.007898:0.008811:0.006163:0.011413:0.017485:0.010843:0.007807:0.003287:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.003287:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.003287:0.010843:0.011756:0.003287:0.011160:0.011302:0.009039:0.011596:0.010820:0.006437:0.009724:0.011071:0.005547:0.008994:0.003287:0.011302:0.009128:0.006211:0.009039:0.007442:0.011048:0.009658:0.009039:0.011596:0.009039:0.005271:0.006437:0.007989:0.004497:0.004109
we assessed genetic variants in genes that are known or predicted to interact with drugs :@0.147059:0.623633:0.886464:0.623633:0.886464:0.603260:0.147059:0.603260:0.014518:0.009039:0.004588:0.009291:0.007533:0.007875:0.009039:0.007533:0.007875:0.009108:0.011391:0.004588:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.004588:0.009838:0.009085:0.007807:0.005798:0.009085:0.011391:0.006437:0.007670:0.004588:0.005615:0.011756:0.004588:0.009656:0.009039:0.011596:0.009039:0.007670:0.004588:0.006620:0.011391:0.008811:0.006437:0.004588:0.009085:0.007442:0.009039:0.004588:0.010706:0.011596:0.010866:0.014723:0.011756:0.004588:0.010843:0.007807:0.004588:0.011071:0.007442:0.009108:0.011391:0.005547:0.009108:0.006209:0.009108:0.011391:0.004588:0.006209:0.011048:0.004588:0.005615:0.011391:0.006209:0.009039:0.007898:0.009291:0.009108:0.006437:0.004588:0.014723:0.005273:0.006620:0.011459:0.004588:0.011391:0.007967:0.011413:0.009724:0.007670:0.004109
according to the drug-gene interaction database resource (DGIdb; :@0.147059:0.644212:0.719778:0.644212:0.719778:0.623839:0.147059:0.623839:0.009291:0.008994:0.008994:0.010843:0.007442:0.011391:0.005615:0.011459:0.009861:0.005981:0.006209:0.011048:0.005981:0.006620:0.011299:0.009039:0.005981:0.011391:0.007967:0.011413:0.009861:0.007533:0.009656:0.009039:0.011596:0.009039:0.005981:0.005615:0.011391:0.006209:0.009039:0.007898:0.009291:0.009108:0.006437:0.005547:0.010843:0.011756:0.005981:0.011573:0.008811:0.006551:0.009108:0.011117:0.009291:0.007873:0.009039:0.005981:0.007442:0.009039:0.007875:0.010820:0.011413:0.007442:0.008994:0.009039:0.005981:0.006939:0.016501:0.015682:0.006620:0.011322:0.011025:0.004497:0.004109
Table S5:@0.721590:0.644212:0.796964:0.644212:0.796964:0.623079:0.721590:0.623079:0.011413:0.009679:0.011528:0.005935:0.009473:0.005844:0.010592:0.010911
) . HGS-:@0.796960:0.644212:0.882361:0.644212:0.882361:0.623839:0.796960:0.623839:0.006939:0.018244:0.004497:0.005981:0.016412:0.015682:0.010112:0.007533
291:@0.803899:0.636596:0.822144:0.636596:0.822144:0.624719:0.803899:0.624719:0.006082:0.006082:0.006082
13.3, LGS-2.2, LGS-5.2, MC-3.1 and MC-3.2 PDOs were markedly less responsive to :@0.147059:0.664791:0.886464:0.664791:0.886464:0.644418:0.147059:0.644418:0.010432:0.010432:0.004497:0.010432:0.004497:0.006483:0.011528:0.015682:0.010112:0.007533:0.010432:0.004497:0.010432:0.004497:0.006483:0.011528:0.015682:0.010112:0.007533:0.010432:0.004497:0.010432:0.004497:0.006483:0.019197:0.014678:0.007533:0.010432:0.004497:0.010432:0.006483:0.009085:0.011596:0.011391:0.006483:0.019197:0.014678:0.007533:0.010432:0.004497:0.010432:0.006483:0.011664:0.016501:0.016255:0.007670:0.006483:0.014518:0.009039:0.007442:0.009039:0.006483:0.017577:0.009085:0.007601:0.010272:0.009108:0.011528:0.005182:0.009724:0.006483:0.005182:0.009039:0.007533:0.007670:0.006483:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007601:0.005547:0.009633:0.009039:0.006483:0.006209:0.011048:0.004109
the pan-HER-inhibitor afatinib compared to their related PDOs, while differences in re-:@0.147059:0.685369:0.882353:0.685369:0.882353:0.664997:0.147059:0.664997:0.006620:0.011299:0.009039:0.003972:0.011365:0.009087:0.011756:0.007533:0.016846:0.012098:0.012349:0.007533:0.005615:0.011870:0.011459:0.005547:0.010820:0.005273:0.006209:0.010843:0.007807:0.003960:0.009085:0.006209:0.008811:0.006437:0.005615:0.011756:0.005547:0.011025:0.003972:0.008994:0.010843:0.017280:0.011365:0.009087:0.007442:0.009108:0.011391:0.003960:0.006209:0.011048:0.003960:0.006622:0.011299:0.009039:0.005615:0.007807:0.003960:0.007442:0.008948:0.005433:0.008811:0.006209:0.009108:0.011391:0.003960:0.011664:0.016504:0.016253:0.007670:0.004497:0.003972:0.014789:0.011459:0.005752:0.005182:0.009039:0.003972:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011596:0.008994:0.009039:0.007670:0.003960:0.005615:0.011756:0.003972:0.007442:0.008991:0.007533
sponse could not be explained by differences in copy number of EGFR/ERBB2(HER2)/:@0.147059:0.705948:0.882353:0.705948:0.882353:0.685575:0.147059:0.685575:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004314:0.008994:0.010820:0.011550:0.005182:0.011391:0.004314:0.011596:0.010820:0.006437:0.004314:0.011254:0.009039:0.004314:0.009108:0.010089:0.011162:0.005433:0.009085:0.005615:0.011596:0.009108:0.011391:0.004314:0.010843:0.009724:0.004314:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011596:0.008994:0.009039:0.007670:0.004314:0.005615:0.011756:0.004314:0.008994:0.010820:0.011094:0.009724:0.004314:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.004314:0.010843:0.006209:0.004314:0.012098:0.015682:0.011276:0.013376:0.007099:0.012098:0.013376:0.012461:0.012646:0.010432:0.006939:0.016846:0.012098:0.013376:0.010432:0.006939:0.007099
ERBB3/ERBB4 (:@0.147059:0.726527:0.290454:0.726527:0.290454:0.706154:0.147059:0.706154:0.012098:0.013376:0.012463:0.012646:0.010432:0.007099:0.012098:0.013376:0.012461:0.012646:0.010432:0.007327:0.006939
Figure 4F, Table S7:@0.290451:0.726527:0.465394:0.726527:0.465394:0.705394:0.290451:0.705394:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.007168:0.010911:0.009382:0.005433:0.007168:0.011413:0.009679:0.011525:0.005935:0.009473:0.007168:0.010592:0.010911
). Despite meeting the criteria of differential re-:@0.465377:0.726527:0.882353:0.726527:0.882353:0.706154:0.465377:0.706154:0.006939:0.004497:0.007327:0.016230:0.009039:0.007510:0.011071:0.005273:0.006209:0.009039:0.007327:0.017485:0.009108:0.009131:0.006437:0.005615:0.011459:0.009861:0.007327:0.006620:0.011299:0.009039:0.007327:0.008994:0.007807:0.005273:0.006209:0.009039:0.007807:0.005798:0.009291:0.007327:0.010843:0.006209:0.007327:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.007327:0.007442:0.009016:0.007533
sponse, all four :@0.147059:0.747106:0.280687:0.747106:0.280687:0.726733:0.147059:0.726733:0.007510:0.011505:0.010843:0.011619:0.007875:0.008743:0.004497:0.005410:0.009405:0.005387:0.005250:0.005410:0.006026:0.010820:0.011413:0.007807:0.004109
BRAF:@0.281994:0.747574:0.336435:0.747574:0.336435:0.725552:0.281994:0.725552:0.013217:0.014038:0.015157:0.012030
-mutant LGS-5 PDOs were classified in the low-responsive sub-:@0.336435:0.747106:0.882353:0.747106:0.882353:0.726733:0.336435:0.726733:0.007533:0.017280:0.011071:0.006551:0.009085:0.011391:0.006437:0.005410:0.011528:0.015682:0.010112:0.007533:0.010432:0.005410:0.011664:0.016504:0.016253:0.007670:0.005410:0.014518:0.009039:0.007442:0.009039:0.005410:0.008765:0.005433:0.009291:0.007533:0.007601:0.005615:0.005684:0.005615:0.009108:0.011391:0.005410:0.005615:0.011756:0.005410:0.006620:0.011299:0.009039:0.005410:0.005182:0.010866:0.014723:0.007533:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007601:0.005547:0.009633:0.009039:0.005410:0.007510:0.011345:0.011041:0.007533
group of afatinib with an IC50-value above the steady state concentration of -0.8 log :@0.147059:0.767684:0.886418:0.767684:0.886418:0.747311:0.147059:0.747311:0.009861:0.007442:0.010820:0.011071:0.011276:0.006688:0.010843:0.006209:0.006688:0.009085:0.006209:0.008811:0.006437:0.005615:0.011756:0.005547:0.011025:0.006688:0.014723:0.005273:0.006620:0.011459:0.006688:0.009085:0.011756:0.006688:0.006825:0.014678:0.010432:0.010432:0.007533:0.009838:0.009402:0.004908:0.011345:0.009039:0.006688:0.009108:0.011254:0.010866:0.009633:0.009039:0.006688:0.006620:0.011299:0.009039:0.006688:0.007510:0.006209:0.009291:0.009291:0.011322:0.009724:0.006688:0.007510:0.006551:0.008811:0.006209:0.009039:0.006688:0.008994:0.010843:0.011596:0.008994:0.009039:0.011391:0.006437:0.007898:0.008811:0.006437:0.005547:0.010843:0.011756:0.006688:0.010845:0.006209:0.006688:0.007533:0.010432:0.004497:0.010432:0.006688:0.005182:0.011048:0.009861:0.004109
μM. The remaining related PDOs with differential response (HGS-13, LGS-2, MC-3) :@0.147059:0.788263:0.886553:0.788263:0.886553:0.767890:0.147059:0.767890:0.010957:0.019608:0.004497:0.006551:0.011470:0.011311:0.009039:0.006551:0.007442:0.009039:0.017577:0.009087:0.005615:0.011756:0.005615:0.011459:0.009861:0.006551:0.007442:0.008948:0.005433:0.008811:0.006209:0.009108:0.011391:0.006551:0.011664:0.016504:0.016253:0.007670:0.006551:0.014723:0.005273:0.006620:0.011459:0.006551:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009402:0.005250:0.006551:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007873:0.009039:0.006551:0.006939:0.016412:0.015682:0.010112:0.007533:0.010432:0.010432:0.004497:0.006551:0.011528:0.015682:0.010112:0.007533:0.010432:0.004497:0.006551:0.019197:0.014678:0.007533:0.010432:0.006939:0.004109
were classified in both the low- and high-responsive subgroup of afatinib. We observed :@0.147059:0.808842:0.886553:0.808842:0.886553:0.788469:0.147059:0.788469:0.014518:0.009039:0.007442:0.009039:0.004839:0.008765:0.005433:0.009291:0.007533:0.007601:0.005615:0.005684:0.005615:0.009108:0.011391:0.004828:0.005615:0.011756:0.004839:0.011254:0.010820:0.006620:0.011459:0.004839:0.006620:0.011299:0.009039:0.004839:0.005182:0.010866:0.014723:0.007533:0.004839:0.009085:0.011596:0.011391:0.004839:0.011459:0.005615:0.009930:0.011459:0.007533:0.007442:0.009039:0.007510:0.011502:0.010843:0.011619:0.007604:0.005545:0.009635:0.009039:0.004839:0.007510:0.011345:0.011025:0.009861:0.007442:0.010820:0.011071:0.011276:0.004828:0.010843:0.006209:0.004839:0.009085:0.006209:0.008811:0.006437:0.005615:0.011756:0.005547:0.010249:0.004497:0.004839:0.018649:0.009039:0.004839:0.010957:0.010934:0.007873:0.009039:0.008400:0.009633:0.009108:0.011391:0.004109
differences in :@0.147059:0.829420:0.267185:0.829420:0.267185:0.809047:0.147059:0.809047:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011596:0.008994:0.009039:0.007670:0.007065:0.005615:0.011756:0.004109
KRAS:@0.270140:0.829889:0.324422:0.829889:0.324422:0.807867:0.270140:0.807867:0.014906:0.014038:0.014655:0.010683
 mutation status between the four PDOs derived from a patient :@0.324422:0.829420:0.886461:0.829420:0.886461:0.809047:0.324422:0.809047:0.007065:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011756:0.007065:0.007510:0.006551:0.008811:0.006163:0.011413:0.007670:0.007065:0.011254:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.007065:0.006620:0.011299:0.009039:0.007065:0.006026:0.010820:0.011413:0.007807:0.007063:0.011664:0.016504:0.016253:0.007670:0.007065:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.007065:0.006414:0.007442:0.010843:0.017645:0.007065:0.009291:0.007065:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.004109
with a mucinous OC (MC-3). The two least responsive PDOs (MC-3.1 and MC-3.2) :@0.147059:0.849999:0.886441:0.849999:0.886441:0.829626:0.147059:0.829626:0.014723:0.005273:0.006620:0.011459:0.006551:0.009291:0.006551:0.017280:0.011345:0.008994:0.005615:0.011596:0.010820:0.011413:0.007670:0.006551:0.016778:0.014678:0.006551:0.006939:0.019197:0.014678:0.007533:0.010432:0.006939:0.004497:0.006551:0.011470:0.011311:0.009039:0.006551:0.006437:0.014518:0.011048:0.006551:0.005182:0.009291:0.009291:0.007510:0.006437:0.006551:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007601:0.005547:0.009633:0.009039:0.006551:0.011664:0.016504:0.016253:0.007670:0.006551:0.006939:0.019197:0.014678:0.007533:0.010432:0.004497:0.010432:0.006551:0.009085:0.011596:0.011391:0.006551:0.019197:0.014678:0.007533:0.010432:0.004497:0.010432:0.006939:0.004109
harbored a :@0.147059:0.870578:0.243682:0.870578:0.243682:0.850205:0.147059:0.850205:0.011391:0.009085:0.007715:0.011254:0.010843:0.007442:0.009108:0.011391:0.004999:0.009288:0.004109
KRAS :@0.244572:0.871047:0.304081:0.871047:0.304081:0.849025:0.244572:0.849025:0.014906:0.014038:0.014655:0.010683:0.005227
hotspot mutation (p.G12V), whereas the other low-responsive PDO :@0.305212:0.870578:0.886476:0.870578:0.886476:0.850205:0.305212:0.850205:0.011299:0.010820:0.006437:0.007510:0.011505:0.010820:0.006437:0.004999:0.017280:0.011073:0.006549:0.008811:0.006437:0.005547:0.010843:0.011756:0.004999:0.006939:0.010500:0.004497:0.015682:0.010432:0.010432:0.015089:0.006939:0.004497:0.004999:0.014792:0.011299:0.009039:0.007442:0.009291:0.009291:0.007670:0.004999:0.006617:0.011302:0.009039:0.004999:0.010820:0.006620:0.011299:0.009039:0.007807:0.004999:0.005184:0.010863:0.014723:0.007533:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007601:0.005547:0.009635:0.009039:0.004999:0.011664:0.016504:0.016412:0.004109
MC-3.4 harbored two different :@0.147059:0.891157:0.419483:0.891157:0.419483:0.870784:0.147059:0.870784:0.019197:0.014678:0.007533:0.010432:0.004497:0.010432:0.006401:0.011391:0.009087:0.007713:0.011254:0.010843:0.007442:0.009108:0.011391:0.006403:0.006437:0.014518:0.011048:0.006403:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.004109
KRAS :@0.421776:0.891625:0.481285:0.891625:0.481285:0.869603:0.421776:0.869603:0.014906:0.014038:0.014655:0.010683:0.005227
mutations (p.L19F and p.Q61E, both reported :@0.484203:0.891157:0.886463:0.891157:0.886463:0.870784:0.484203:0.870784:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.006403:0.006939:0.010500:0.004497:0.011619:0.010432:0.010432:0.011276:0.006401:0.009085:0.011596:0.011391:0.006403:0.010500:0.004497:0.016344:0.010432:0.010432:0.012098:0.004497:0.006403:0.011254:0.010820:0.006620:0.011459:0.006403:0.007442:0.009131:0.011502:0.010845:0.007964:0.006211:0.009106:0.011391:0.004109
to have an attenuated phenotype compared to hotspot mutations:@0.147059:0.911735:0.698556:0.911735:0.698556:0.891362:0.147059:0.891362:0.006209:0.011048:0.005205:0.011391:0.008928:0.009633:0.009039:0.005205:0.009085:0.011756:0.005205:0.008811:0.006161:0.006211:0.009039:0.011391:0.011596:0.008811:0.006209:0.009108:0.011391:0.005205:0.011162:0.011299:0.009039:0.011596:0.010820:0.006437:0.009724:0.011505:0.009039:0.005205:0.008994:0.010843:0.017280:0.011368:0.009085:0.007442:0.009108:0.011391:0.005205:0.006209:0.011048:0.005205:0.011299:0.010820:0.006437:0.007510:0.011505:0.010820:0.006437:0.005205:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670
294,295:@0.698580:0.904119:0.737692:0.904119:0.737692:0.892242:0.698580:0.892242:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
 and the high-re-:@0.737690:0.911735:0.882353:0.911735:0.882353:0.891362:0.737690:0.891362:0.005205:0.009085:0.011598:0.011391:0.005205:0.006620:0.011299:0.009039:0.005205:0.011459:0.005615:0.009930:0.011459:0.007533:0.007442:0.009046:0.007533